Understanding CAR-M Technology With Carisma Therapeutics' Dr. Debora Barton
Source: Cell & Gene
Carisma Therapeutics’ Dr. Barton breaks down the latest in CAR-M technology as well as the company's Phase 1 First-in-Human Study of Adenovirally Transduced Anti-HER2 CAR Macrophages in Subjects with HER2 Overexpressing Solid Tumors.
This website uses cookies to ensure you get the best experience on our website. Learn more